Prognostic potential of circulating tumor DNA detection at different time periods in resectable non-small cell lung cancer: Evidence from a meta-analysis

This study was undertaken to evaluate the prognostic significance of circulating tumour DNA (ctDNA) detection at different time periods in resectable non-small cell lung cancer (NSCLC). A comprehensive search strategy was conducted through the electronic platforms published up to June 2022. In total, 7 studies with 1138 patients were included. Patients with positive ctDNA have an increased risk of recurrence and mortality. The association between risk of recurrence and detectable ctDNA after surgery 3 days-2 weeks and 1–3 months was stronger than detected at 1 week before surgery. The predictive value of longitudinal detection ctDNA for recurrence and mortality was not stronger than at other time periods. In conclusion, ctDNA is a promising biomarker for predictive recurrence and survival in resectable NSCLC patients. The ctDNA detection after surgery 3 days-2 weeks with more reliably and feasible in identifying resectable NSCLC patients at high risk for recurrence.